

cells



Article

Beneficial Effect of ACI-24 Vaccination on A β Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model

Jasenka Rudan Njavro, Marija Vukicevic, Emma Fiorini, Lina Dinkel, Stephan A. Müller, Anna Berghofer, Chiara Bordier, Stanislav Kozlov, Annett Halle, Katrin Buschmann et al.

Special Issue

The Role of Inflammation in Neurodegenerative Diseases and Its Therapeutic Prospects

Edited by

Dr. Dolores Viña



<https://doi.org/10.3390/cells12010079>

Article

Beneficial Effect of ACI-24 Vaccination on A β Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model

Jasenka Rudan Njavro ¹, Marija Vukicevic ², Emma Fiorini ², Lina Dinkel ¹, Stephan A. Müller ^{1,3}, Anna Berghofer ³, Chiara Bordier ¹, Stanislav Kozlov ⁴ , Annett Halle ⁴, Katrin Buschmann ⁵, Anja Capell ⁵, Camilla Giudici ¹, Michael Willem ⁵, Regina Feederle ^{1,6,7} , Stefan F. Lichtenthaler ^{1,3,7} , Chiara Babolin ², Paolo Montanari ², Andrea Pfeifer ², Marie Kosco-Vilbois ² and Sabina Tahirovic ^{1,*} 

¹ German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany

² AC Immune SA, 1015 Lausanne, Switzerland

³ Neuroproteomics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 80333 Munich, Germany

⁴ German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany

⁵ Biomedical Center (BMC), Ludwig-Maximilians University Munich, 80539 Munich, Germany

⁶ Monoclonal Antibody Core Facility, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany

⁷ Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany

* Correspondence: sabina.tahirovic@dzne.de

Abstract: Amyloid- β (A β) deposition is an initiating factor in Alzheimer's disease (AD). Microglia are the brain immune cells that surround and phagocytose A β plaques, but their phagocytic capacity declines in AD. This is in agreement with studies that associate AD risk loci with genes regulating the phagocytic function of immune cells. Immunotherapies are currently pursued as strategies against AD and there are increased efforts to understand the role of the immune system in ameliorating AD pathology. Here, we evaluated the effect of the A β targeting ACI-24 vaccine in reducing AD pathology in an amyloidosis mouse model. ACI-24 vaccination elicited a robust and sustained antibody response in APPS1 mice with an accompanying reduction of A β plaque load, A β plaque-associated ApoE and dystrophic neurites as compared to non-vaccinated controls. Furthermore, an increased number of NLRP3-positive plaque-associated microglia was observed following ACI-24 vaccination. In contrast to this local microglial activation at A β plaques, we observed a more ramified morphology of A β plaque-distant microglia compared to non-vaccinated controls. Accordingly, bulk transcriptomic analysis revealed a trend towards the reduced expression of several disease-associated microglia (DAM) signatures that is in line with the reduced A β plaque load triggered by ACI-24 vaccination. Our study demonstrates that administration of the A β targeting vaccine ACI-24 reduces AD pathology, suggesting its use as a safe and cost-effective AD therapeutic intervention.

Keywords: Alzheimer's disease; immunotherapy; microglia; A β vaccine; ACI-24



Citation: Rudan Njavro, J.; Vukicevic, M.; Fiorini, E.; Dinkel, L.; Müller, S.A.; Berghofer, A.; Bordier, C.; Kozlov, S.; Halle, A.; Buschmann, K.; et al. Beneficial Effect of ACI-24 Vaccination on A β Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model. *Cells* **2023**, *12*, 79. <https://doi.org/10.3390/cells12010079>

Academic Editor: Dolores Viña

Received: 14 November 2022

Revised: 9 December 2022

Accepted: 20 December 2022

Published: 24 December 2022



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Accumulation of amyloid- β (A β) is hypothesised to be an early event in a complex neurodegenerative cascade that leads to cognitive and functional impairments in Alzheimer's disease (AD) [1,2]. There are multiple lines of evidence for an imbalance between production and clearance of A β as the initiating factor in AD pathology. Therefore, A β has emerged as the most extensively pursued therapeutic target [3]. Microglia are immune cells in the brain that surround and phagocytose A β plaques [4–6]. Interestingly, during aging and in AD, their phagocytic capacity declines [7–10]. The importance of microglial phagocytic capacity is emphasised in a number of genome-wide association studies that identified different microglial genes associated with increased risk of developing AD [11]. The identified risk genes are functionally linked with defects in endo-lysosomal pathway,

phagocytosis and A β clearance [12]. These changes are reflected by RNA signatures of microglia under varying pathological conditions classified as homeostatic, ageing and disease-associated [13–18]. Furthermore, this is supported by our proteomic analysis of microglia isolated from mouse models of amyloidosis (Microglial A β Response Proteins; MARPs) that revealed molecular alterations, correlating with the decline of their phagocytic function [10]. Importantly, microglia in the brain of AD patients bear the potential for repair as reflected by their enhanced A β clearance [19]. We have previously shown, using an ex vivo model of AD, that factors secreted by microglia isolated from young (postnatal) mice induced proliferation of aged microglia and reduced A β plaque load [9], underscoring the importance of exploring therapeutic strategies that enhance microglial clearance to reduce A β burden.

Immunotherapy is a therapeutic strategy gaining clinical validation to alter the disease progression and pathology associated with AD [20]. The ground-breaking approach of immunising AD mouse models with the full-length A β sequence (1–42) demonstrated that the development of A β plaques could be prevented [21]. Indeed, the first vaccine, AN1792, incorporating the full-length A β sequence (1–42), established an early clinical proof of concept [22,23]. However, 6% of patients developed meningoencephalitis [24], a severe side effect attributed to the T cell mediated response against the mid-region of the A β sequence (10–24) where the dominant T cell epitope is located [25]. Therefore, next generation vaccines utilised antigens from the N-terminal part of the A β sequence to avoid an unwanted autoimmune reaction [26,27]. Together with the active immunisation, passive immunotherapy corroborated the strategy to target A β . Aducanumab, a human monoclonal antibody (mAb) that selectively targets A β aggregates, provided substantial evidence for efficacy in reducing A β [19] and is the first FDA approved drug for the mechanism-based therapy against AD [20]. Recent clinical advancements of several anti-A β mAbs further support the feasibility of reducing A β burden, despite having difficulties reaching all predefined primary and secondary endpoints [28–32]. Excitingly, a recent press release reported that mAb lecanemab met both primary and secondary endpoints (<https://www.bioarctic.se/en/lecanemab-phase-3-clarity-ad-study-in-early-alzheimers-disease-meets-primary-and-all-key-secondary-endpoints-with-high-statistical-significance-5808/>; accessed on 8 November 2022), strongly supporting the therapeutic benefits of targeting A β . Along these lines, targeting of pre-amyloid seeds can efficiently reduce Alzheimer-like pathology in amyloidosis mice [33], supporting the efficacy of early disease intervention strategies.

Although both active and passive immunisation strategies may show beneficial effects on A β pathology, active immunisation offers important advantages. Vaccines are cost-effective, can generate a long-term polyclonal disease modifying response and can be introduced as a prevention strategy [34]. Thus, an active immunisation approach may prove to be more effective in slowing the cognitive decline. Furthermore, the most common safety concern of immunotherapy, the A β -related imaging abnormalities (ARIA) reported for several anti-A β monoclonal antibodies [19,28,30,32,35], seem to be less frequent for A β targeting vaccines [36–40].

It is, therefore, important to generate new vaccines with the potential to reduce A β and improve cognitive decline. ACI-24 is a liposomal vaccine that anchors the A β sequence (1–15) between palmitoylated lysine tandems, thereby adopting the aggregating beta-sheet structure [41]. Pre-clinical studies using ACI-24 showed that vaccination prevents memory defects in mouse models of amyloidosis [41] and Down syndrome [42]. Furthermore, the produced antibodies were more specific for aggregated A β , including oligomers, with minor reactivity to monomers [41,43], underscoring the specificity of this vaccine towards pathological forms of A β . Recently, an optimised formulation of ACI-24 has been developed, harbouring additional non-target T cell epitopes. This modification improves the immune response and triggers high titres against the neurotoxic and pathological species pyroglutamate A β 3–42 [44–46].

We show here that the efficacy of the ACI-24 vaccine is linked to the severity of A β deposition. Although ACI-24 elicited a substantial immune response in all vaccinated APPPS1 [47] animals, AD pathology, including A β plaque load, A β plaque associated ApoE and dystrophic neurites, could be more robustly reduced when vaccination was initiated at stages with less severe A β deposition. Furthermore, we observed an increased proportion of inflammasome component NLRP3-positive plaque-associated microglia following ACI-24 vaccination. In contrast to this local microglial activation at A β plaques, globally, we observed a more ramified morphology of A β plaque-distant microglia, supporting beneficial effects of ACI-24 vaccination on microglial phenotypes. Accordingly, bulk transcriptomic analysis revealed a trend towards reduction in the expression of several disease-associated microglia (DAM) signatures that is in line with reduced A β plaque load triggered by ACI-24 vaccination.

Taken together, this *in vivo* study shows the strength of the ACI-24 vaccine in triggering robust immune responses and effectively reducing AD pathology. Our work supports the concept of using a vaccine approach as a safe and cost-effective AD therapeutic intervention and initiating preventive trials at early stages of A β plaque deposition.

2. Materials and Methods

2.1. Animals

Female mice from the hemizygous APPPS1 mouse line overexpressing human APPKM670/671NL and PS1L166P under the Thy-1 promoter [47] were used in this study. Mice were bred on a wild-type (WT) C57BL/6J background with *ad libitum* access to water and standard mouse chow (Ssniff Ms-H, Ssniff Spezialdiäten GmbH, Soest, Germany). ApoE knock-out mice (B6.129P2-Apoetm1Unc/J) [48] were used for the generation of mouse ApoE antibodies. Animals were kept under a 12/12 h light–dark cycle. All animal experiments were carried out in accordance with the German animal welfare law and have been approved by the government of Upper Bavaria (ROB-55.2-2532.Vet_02-17-153 and ROB-55.2-2532.Vet_03-17-68).

2.2. Animal Treatment

Six-week-old female APPPS1 littermates were subcutaneously injected with 200 μ L of ACI-24 (80 μ g per dose of antigen) [41] or PBS (10010056, Gibco) as control. Mice were vaccinated every 2 weeks until 10 weeks of age (in total 3 doses of the vaccine) as schematically outlined in Figure 1A. At the age of 12 weeks, mice were sacrificed, re-genotyped and brains and plasma were collected for further analysis. The cohort size was 10 animals per condition ($n = 10$) for the immunohistochemical and biochemical analysis. The control group consisted of 10 female APPPS1 animals (5 were offspring of a transgenic father and WT mother, and 5 were offspring of a transgenic mother and WT father). The ACI-24 treated group included 10 female animals (4 transgenic father and 6 transgenic mother offspring). The proteomic cohort consisted of 5 control (3 transgenic father and 2 transgenic mother offspring) and 6 ACI-24 treated animals (3 transgenic father and 3 transgenic mother offspring).

2.3. Blood Collection

Blood was collected before the first immunisation (baseline), and at one, three and six weeks after the first immunisation (Figure 1A). Blood samples were collected from the facial vein using animal lancet (GR 5 MM, Braintree Scientific, Braintree, MA, USA) or by a heart puncture at the end of the study. Samples were collected in heparin tubes (16.443, Sarstedt, Nümbrecht, Germany), mixed up and down by inverting the tube at least 4 times, and kept on ice until further processing. Blood was then centrifuged at $17,000\times g$ for 10 min at 4 °C to collect the plasma. Supernatant was aliquoted and stored at -80 °C until analysis.




Figure 1. ACI-24 vaccination efficiently reduces Aβ plaque load in APPPS1 mice. Schematic overview of the vaccination paradigm (A). ELISA analysis of the anti-Aβ42 total IgG titres (ng/mL) in plasma (B). Control APPPS1 mice (PBS treated, in dotted grey) have the baseline titres, while both ACI-24 vaccinated APPPS1 (in red) and ACI-24 vaccinated WT mice (in black) have robust and sustained immune response. Representative images of Aβ (as stained with NAB228 antibody) and nuclei (Hoechst) in cortical sections show decreased Aβ deposition following ACI-24 vaccination. Scale bar for images in the centre column is indicating 200 μm, and scale bar for images in the right column (magnification of dotted boxed regions from centre column images) is indicating 50 μm (C). Statistical analysis of 10 control and 10 ACI-24 vaccinated APPPS1 mice for Aβ plaque coverage (D), number (E) and size (F). ACI-24 significantly downregulated Aβ plaque coverage and size. Offspring are from the transgenic mother (pink circles) or father (blue circles). Graphs are presented as mean ± SEM (* $p < 0.05$, ** $p < 0.001$, unpaired two-tailed Student's t -test).

2.4. Quantification of Antigen-Specific Antibodies

Specific anti-Aβ1-42 IgG was measured by ELISA as previously described [46]. Briefly, plates were coated with 10 μg/mL Aβ1-42 peptide film (Bachem, Bubendorf, Switzerland) overnight at 4 °C. After washing the plate with PBS/0.05% Tween 20 and blocking with 1% BSA/PBS/0.05% Tween 20 for 1 h at 37 °C, the plasma was added in serial dilutions

(1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400 and 1:12,800) and incubated for 2 h at 37 °C. The 6E10 antibody (dilution 1:1600, 803002, Biolegend, Amsterdam, Netherlands) was used as a standard and 4G8 (dilution 1:5000, 800702, Biolegend, Amsterdam, Netherlands) as a positive control. After washing, plates were incubated with the detection antibody, an alkaline phosphatase conjugated anti-mouse IgG (dilution 1:7000, 115-055-164, Jackson ImmunoResearch Europe, Ely, UK) for 2 h at 37 °C. After washing, plates were incubated with the phosphatase substrate pNPP (S0942, Sigma-Aldrich, Merck, Taufkirchen, Germany) and read at 405 nm by using an ELISA plate reader. Results are expressed with reference to the serial dilution of the 6E10 antibody.

2.5. Generation of the ApoE Antibody 26C11

A peptide comprising amino acids $_{20}$ GEPEVTDQLEWQSN $_{33}$ of mouse ApoE protein was synthesised and coupled to OVA (Peps4LS, Heidelberg, Germany). ApoE knock-out mice were immunised with a mixture of 40 µg peptide, 6 nmol CpG oligonucleotide 1668 (Tib Molbiol, Berlin, Germany) in 200 µL PBS and 200 µL incomplete Freund's adjuvant. A boost without adjuvant was given 14 weeks after the primary injection. Fusion of mouse spleen cells with the myeloma cell line P3X63-Ag8.653 (ATCC; CRL-1580) was performed using standard procedures. Hybridoma supernatants were tested in a flow cytometry assay (iQue, Intellicyt; Sartorius, Göttingen, Germany) for binding to biotinylated ApoE peptide coupled to streptavidin beads (PolyAN, Berlin, Germany). Using Atto-488-coupled isotype-specific monoclonal rat-anti-mouse IgG secondary antibodies, antibody binding was analysed using ForeCyt software v9.0 (Sartorius, Goettingen, Germany). Positive supernatants were further analysed by Western blot analysis and selected hybridoma cells were subcloned by limiting dilution to obtain stable monoclonal cell lines. Experiments in this work were performed with hybridoma supernatant of clone APO1M 26C11 (mouse IgG2b/κ).

2.6. Immunohistochemistry

The brain was perfused with 0.9% NaCl isotonic solution for 5 min (B. Braun, Mel-sungen, Germany) and the right hemisphere was post-fixed in 4% paraformaldehyde in 0.1 M PBS for 6 h. Hemispheres were cryoprotected (30% sucrose in 0.1 M PBS), embedded in Optimal Cutting Temperature medium (4583, Science Services, München, Germany) on dry ice and stored at −80 °C until sectioning. Sagittal sections (30 µm thick) were cut using a cryostat (CryoSTAR NX70, Thermo Fisher Scientific, Schwerte, Germany) and placed in 0.1 M PBS for direct staining. Alternatively, sections were stored in anti-freezing solution (30% glycerol, 30% ethylenglycol, 10% 0.1 M PBS, pH 7.2–7.4 and 30% dH₂O) at −20 °C and washed in 0.1 M PBS before staining. For ApoE antibody, antigen retrieval step was carried out before permeabilization. Sections were incubated in pre-warmed 10 mM citric acid buffer pH 6 for 20 min at 96 °C with shaking. Afterwards, sections were washed with PBS. When using primary mouse antibodies, sections were permeabilized in PBS/0.5% Triton X-100 for 30 min, followed by 1 h incubation in FAB fragment at room temperature to block for unspecific epitopes (1:100 in PBS, 715-007-003, Jackson ImmunoResearch Europe, Ely, UK) and washed in PBS/0.2% Triton X-100 before blocking. For all the other primary antibodies, sections were directly permeabilized and blocked in PBS/0.5% Triton X-100/5% normal goat or donkey serum for 1 h at room temperature and incubated overnight at 4 °C in primary antibody diluted in blocking solution. After washing with PBS/0.2% Triton X-100, sections were incubated in appropriate fluorophore-conjugated secondary antibodies (1:500, Life Technologies) together with nuclear stain Hoechst 33342 (1:2000, H3570, Thermo Fisher Scientific, Schwerte, Germany) and dense fibrillar plaque core staining Thiazin red (1:1000 dilution, 12648, Morphisto, Offenbach am Main, Germany) or Methoxy-X04 (1:10,000, ab142818, Abcam, Cambridge, UK) for 2 h at room temperature. After washing, sections were mounted onto glass slides (Thermo Fisher Scientific, Schwerte, Germany), dried for 1 h, mounted using Gel Aqua Mount media (F4680, Sigma-Aldrich, Merck, Taufkirchen, Germany) and analysed by confocal microscopy.

Primary antibodies used: A β 3552 (0.74 μ g/mL) [49], A β NAB228 (1:500, sc-32277, Santa Cruz Biotechnology, Heidelberg, Germany) [10], BACE1 (1:400, ab108394, Abcam, Cambridge, UK), ApoE (1:200, hybridoma supernatant, clone 26C11), IBA1 (1:500, ab5076, Abcam, Cambridge, UK), IBA1 (1:500, 234308, Synaptic Systems, Göttingen, Germany), NLRP3 (1:50, BSS-BS-10021R-100, Biozol Diagnostics Vertrieb, Eching, Germany) and CD68 (1:500, MCA1957GA, Bio-Rad, Feldkirchen, Germany).

2.7. Image Acquisition, Analysis and Quantification

All quantifications were performed by investigators blinded to experimental conditions. For the quantification of total A β (NAB228 antibody), fibrillar A β (Thiazin red staining), ApoE and BACE1, 16 images per brain were systematically taken from comparable neocortical regions using a confocal microscope (Zeiss LSM 900). Quantification was performed using a self-programmed macro with ImageJ software v.1.53c.

For the microglial recruitment analysis and CD68 coverage, randomly selected plaques from the neocortical region were imaged (30 images per brain) as described previously [10]. Within the same experiment, microscopy acquisition settings were kept constant. For every image, maximal intensity projection was created from every z-stack using ImageJ software v.1.53c. A defined region of interest (ROI) was manually drawn around every plaque and measured for the A β and CD68 coverage area. The number of microglia (Iba1 + cells) recruited to the plaque area was counted within the ROI and through the z-stack. Total CD68 coverage area was normalised to the number of microglia (Iba1+ cells) recruited to the plaque within the ROI. The number of microglial cells at A β plaques was normalised to the area covered by A β (3552 antibody) and expressed as number of microglial cells per μ m² of A β plaque.

For the characterisation of NLRP3 activation in plaque-associated microglia, randomly selected confocal images (Z-stack 25 μ m; slice distance (Z) 0.5 μ m) from the neocortical region were acquired with a 40 $\times$ objective (8 images per animal, each containing 1–5 plaques). Images were analysed using Imaris (Imaris 9.2.1). The total number of cells positive for NLRP3 was quantified manually and normalised to the total number of plaque-associated microglia.

For the microglial morphology analysis, randomly selected images from the neocortical region were acquired with a 40 $\times$ objective at a resolution of 1024 $\times$ 1024 pixels and a slice distance (Z) of 0.4 μ m using the maximum possible number of Z-stacks. Analysis was carried out manually using ImageJ as previously described [50]. Briefly, single microglia (IBA1 positive cells) that were clearly distinguishable from one another and at least 1.5 plaque diameter away were selected through the Z-stack (8–14 microglia per brain). The threshold was adjusted, and the noise was removed from the binary image. The cells were further analysed with the plugin Sholl analysis 4.1.1 by measuring the maximum radius of the cell soma, the radius of the longest branch of the cell and the number of primary branches. Schoenen ramification index (RI) was automatically calculated (number of end branches/number of primary branches) and collected for each cell. Area and perimeter of the cell were also measured to calculate the circularity index ($4\pi[\text{area}]/[\text{perimeter}]^2$).

2.8. Biochemical Analysis of the Brain

The brain was perfused with 0.9% NaCl isotonic solution for 5 min (B. Braun, Melsungen, Germany) and the left hemisphere (without olfactory bulb, brain stem and cerebellum) was snap frozen and subsequently pulverised using CP02 cryoPREP Automated Dry Pulverizer (Covaris, Brighton, UK) and liquid nitrogen. Pulverised hemispheres were stored at -80°C until processing. Aliquots of brain powder were lysed on ice for 30 min in lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% Triton X-100) supplemented with protease and phosphatase inhibitor cocktail (Roche). Samples were then centrifuged at 17,000 $\times$ g for 30 min at 4°C and supernatants were collected (Triton X-100 soluble fraction). Pellets were further resuspended in 70% formic acid (FA), sonicated for 5 min and centrifuged at

186,000× *g* for 30 min at 4 °C. FA supernatants (formic acid soluble fraction) were then diluted 1:20 in neutralisation buffer (1 M Tris base, pH 9.5).

For Western blot analysis, the protein content from Triton X-100 soluble fraction was quantified using BC assay (UP40840A, Interchim, Montluçon, France) according to manufacturer's protocol with a NanoQuant Infinite M200 Pro. A total of 10 to 20 µg of protein was loaded on a Novex 10–20% tricine protein gel (EC66252BOX, Thermo Fisher Scientific, Schwerte, Germany), followed by blotting on nitrocellulose membrane (Merck, Taufkirchen, Germany) using anti-Aβ 2D8 (1:50) [49] and anti-β-actin (1:1000, A5316, Sigma-Aldrich, Merck, Taufkirchen, Germany) as a loading control. Blots were developed using horseradish peroxidase-conjugated secondary antibodies (Promega, Walldorf, Germany) and the ECL chemiluminescence system (Amersham Biosciences Europe, Freiburg im Breisgau, Germany) with an ImageQuant LAS 4000 series.

ELISA analysis of Aβ was carried out according to the manufacturer's protocol (K15200G, MSD, Rockville, MD, USA). A total of 10 µg of protein from the Triton X-100 soluble fraction was loaded, while the formic acid soluble fraction was loaded according to the protein amount of the Triton X-100 soluble fraction (diluted at least in 1 to 5 ratio).

2.9. Brain Gene Expression Profiling

An aliquot of 20 to 30 mg of the pulverised hemispheres (without olfactory bulb, brain stem and cerebellum) was taken for the total RNA extraction. Total RNA was isolated using the RNeasy Mini kit (74104, Qiagen, Hilden, Germany) and the quality of the sample was assessed using the Agilent RNA 6000 Nano Kit (5067-1511, Agilent technologies, Waldbronn, Germany) according to the manufacturer's instruction. A total of 100 ng RNA per sample was subjected to gene expression profiling using the nCounter® Neuropathology panel and Glial Profiling panel from NanoString (NanoString Technologies, Seattle, WA, USA). Data were analysed using the nSolver Analysis Software, version 4.0. The background of all the samples was subtracted using a threshold with a defined value of 20. Thereafter, gene expression levels in each sample were normalised against the geometric mean of positive controls and housekeeping genes (provided by the panel; excluding genes with CV higher than 20% from the lowest sample and excluding genes with the average count less than 100).

2.10. Isolation of Primary Microglia

After the brain had been removed from the skull, the olfactory bulb, brain stem and cerebellum were removed, meninges cleaned and primary microglia were acutely isolated (without culturing) from the remaining cerebrum using MACS technology (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer's instructions and as previously described, with some modification [51]. Samples were dissociated, first by enzymatic digestion using papain (200 U, P3125, Sigma-Aldrich, Merck, Taufkirchen, Germany) and afterwards with mechanical dissociation using three fire-polished glass Pasteur pipettes of decreasing diameter. CD11b+ microglia were magnetically separated (Miltenyi Biotec, Bergisch Gladbach, Germany) to obtain CD11b-enriched (microglia-enriched) and CD11b-depleted (microglia-depleted) fractions. After two washes with HBSS (Gibco, supplemented with 7 mM HEPES), microglia-enriched pellets were frozen in liquid nitrogen and stored at −80 °C until processing.

2.11. Sample Preparation for Proteomics

Microglia-enriched pellets from 5 APPPS1 mice (3 transgenic father and 2 transgenic mother offspring) treated with PBS and 6 APPPS1 mice (3 transgenic father and 3 transgenic mother offspring) treated with ACI-24 were subjected to proteomic analysis. The cell pellets were lysed in 200 µL of STET lysis buffer (50 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% Triton, pH 7.5) at 4 °C with intermediate vortexing. The samples were centrifuged for 5 min at 16,000× *g* at 4 °C to remove cell debris and undissolved material. The supernatant was transferred to a protein LoBind tube (Eppendorf) and the protein concentration estimated

using the Pierce 660 nm protein assay (Thermo Fisher Scientific, Schwerte, Germany). A protein amount of 15 µg per sample was subjected to tryptic digestion. First, 100 mM MgCl₂ was added to a final concentration of 10 mM and DNA was digested with 25 units Benzonase (Sigma-Aldrich, Merck, St. Louis, MO, USA) for 30 min at 37 °C. Proteins were reduced at 37 °C for 30 min with 15 mM dithiothreitol (DTT) followed by cysteine alkylation with 60 mM iodoacetamide (IAA) for 30 min at 20 °C. Excess of IAA was removed by adding DTT. Detergent removal and subsequent digestion with 0.2 µg LysC and 0.2 µg trypsin (Promega, Walldorf, Germany) were performed using the single-pot, solid-phase-enhanced sample preparation as previously described [52]. After vacuum centrifugation, peptides were dissolved in 20 µL of 0.1% formic acid (Biosolve Chimie, Dieuze, France) and indexed retention time peptides were added (iRT Kit, Biognosys, Schlieren, Switzerland).

2.12. LC-MS/MS Analysis

The LC-MS/MS analyses were performed on a nanoElute system (Bruker Daltonics, Bremen, Germany) which was online coupled with a timsTOF pro mass spectrometer (Bruker Daltonics, Bremen, Germany). An amount of 400 ng of peptides per sample were separated on a self-packed 15 cm C18 column (75 µm ID) packed with ReproSil-Pur 120 C18-AQ resin (1.9 µm, Dr. Maisch GmbH, Ammerbuch, Germany). For peptide separation, a binary gradient of water and acetonitrile (B) with a length of 120 min was applied at a flow rate of 300 nL/min and a column temperature of 50 °C (0 min: 2% B; 2 min: 5% B; 94 min: 24% B; 112 min: 35% B; 120 min: 60% B).

A Data Independent Acquisition Parallel Accumulation Serial Fragmentation (DIA-PASEF) method was used. One MS1 full scan was followed by 32 sequential DIA windows with 26 *m/z* width for peptide fragment ion spectra with an overlap of 1 *m/z* covering a scan range of 400 to 1201 *m/z*. The ramp time was fixed to 100 ms and 2 windows were scanned per ramp. This resulted in a total cycle time of 1.8 s.

The software DIA-NN version 1.8 was used to analyse the data [53]. The raw data were searched against a one protein per gene database from *Mus musculus* (UniProt, 21966 entries, download: 09-04-2021) using a library free search. Trypsin was defined as protease and 2 missed cleavages were allowed. Oxidation of methionines and acetylation of protein N-termini were defined as variable modifications, whereas carbamidomethylation of cysteines was defined as fixed modification. The precursor and fragment ion *m/z* ranges were limited from 400 to 1201 and 200 to 1700, respectively. An FDR threshold of 1% was applied for peptide and protein identifications. The mass accuracy and ion mobility windows were automatically adjusted by the software. The match between runs option was enabled.

Generated label-free quantification (LFQ) outputs were log₂ transformed and an average log₂ fold change was calculated for each protein, which was identified with at least 2 unique peptides in at least 2 biological replicates per condition. Changes in protein abundance were evaluated using a Student's *t*-test between the log₂ LFQ intensities of the two experimental groups. A permutation-based FDR estimation was used to account for multiple hypotheses (*p* = 5%; *s*₀ = 0.1) using the software Perseus 1.6.14.0. Volcanos only display proteins, which were identified often enough to apply statistical tests [54,55].

3. Results

3.1. ACI-24 Triggers Substantial Immune Response

To investigate the effect of the ACI-24 vaccine, we performed an in vivo study using a fast-progressing amyloidosis mouse model APPPS1 [47]. Aβ deposition in this mouse model is first detectable in the cortex at the age of six to eight weeks [47]. ACI-24 vaccination was initiated at the age of six weeks, thus together with the onset of the Aβ deposition. The vaccination paradigm included three doses of the vaccine or PBS control applied every two weeks and the blood was collected at baseline, between each vaccination and at the end of the study as outlined (Figure 1A). To avoid sex-specific differences in Aβ pathology, only female animals were included into the study. The study ended at 12 weeks of age, when the Aβ pathology is already abundant throughout the cortex [10,47]. The ACI-24 vaccine

triggered a robust immune response as measured by the anti-A β 42 IgG antibody titres detectable in the plasma (Figure 1B). The anti-A β 42 IgG antibody titres were observed seven days after the first vaccination and sustained throughout the study. We observed comparable anti-A β 42 total IgG levels following the vaccination of APPPS1 and WT mice. In contrast with the ACI-24 vaccinated mice, this immune response was not measurable in the mice injected with PBS as a control.

3.2. ACI-24 Reduces A β Load in APPPS1 Mice

To analyse the effects of the ACI-24 on A β pathology, we performed an immunohistochemical analysis of cortical A β deposition. ACI-24 vaccination had significant effects on the plaque pathology (Figure 1C). We observed a significant reduction in the A β plaque coverage using the anti-A β antibody NAB228 (Figure 1C,D). Additionally, the A β plaque number showed trends to reduction following vaccination (Figure 1E). In agreement with the reduction of the A β coverage, the A β plaque size was also significantly decreased in the ACI-24 vaccinated mice (Figure 1F). Surprisingly, we identified two subpopulations of analysed female mice that had clearly visible differences in the A β plaque load, regardless of the vaccination. The mice that had higher A β plaque pathology were the offspring of a transgenic father and a WT mother (Figure 1D–F, marked in blue circles), while the mice with the lower A β plaque burden were animals bred with the opposite mating scheme—transgenic mother and a WT father (Figure 1D–F, marked in pink circles). When we separated the two subgroups of the control treated mice, there was a significantly higher coverage and number, and a trend towards increased size of A β plaques, in the offspring generated by the transgenic father compared to the transgenic mother (Supplementary Figure S1A–D). Thus, the transgenic father offspring developed a more pronounced A β pathology, compared to the transgenic mother offspring.

Taken together, ACI-24 shows a downregulation of coverage and size of the A β plaques in all vaccinated animals. Notably, we observed differences in the A β plaque load depending on which parent is carrying the APPPS1 transgene, providing us with the rationale for the observed experimental heterogeneity.

3.3. ACI-24 More Effectively Reduces A β Pathology in the Offspring Generated by the Transgenic Mother

Since we observed differences in the A β plaque load depending on which parent is carrying the APPPS1 transgene, we next separately analysed the efficacy of ACI-24 vaccination according to the mating scheme. The transgenic father offspring had a minor effect on A β plaque pathology following ACI-24 vaccination (Supplementary Figure S2A–C). In contrast, the analysis of the transgenic mother offspring revealed a significantly reduced A β coverage, plaque number and plaque size following ACI-24 vaccination (Figure 2A–C and Supplementary Figure S3). In line with these results, we observed a significant reduction in the coverage and number of fibrillar A β plaques as well as trends to reduced size of the fibrillar A β plaques (Figure 2D–F and Supplementary Figure S3). Next, we analysed levels of the Triton X-100 extractable (soluble) and formic acid extractable (insoluble) A β in the cerebrum of the vaccinated mice via Western blotting (Figure 2G). Transgenic mother offspring had a significant decrease in the A β in the Triton X-100 and formic acid soluble fractions following ACI-24 vaccination (Figure 2H,I). To investigate different A β species, we performed MSD ELISA of soluble and insoluble A β and observed a trend towards reduction of both A β 40 and A β 42 species in both fractions of the transgenic mother offspring (Figure 2J,K), supporting the immunohistochemical and Western blot data.

Overall, we demonstrate a more consistent and robust reduction of the A β pathology following ACI-24 vaccination in the offspring generated by the transgenic mother, supporting the hypothesis that lower A β load is of advantage for the vaccination efficacy.




Figure 2. ACI-24 effectively reduces Aβ pathology in the offspring generated by the transgenic mother. Statistical analysis of 5 control and 6 ACI-24 vaccinated mice (transgenic mother offspring) for Aβ plaque coverage (A), number (B) and size (C) and fibrillar Aβ plaque coverage (D), number (E) and size (F). Representative images (G) and quantifications (H,I) of Western blot analysis of Triton X-100 soluble and formic acid soluble Aβ. Of note, representative samples (G) were not loaded next to each other, but on the same membrane. Therefore, they are separated by the dashed line. ACI-24 vaccination leads to significant reduction of Aβ in Triton X-100 soluble and formic acid soluble fractions. β-actin represents the loading control. ELISA analysis of Triton X-100 soluble (J)

and formic acid soluble A β (K) fractions demonstrates a trend towards reduction of both A β 40 and A β 42 in ACI-24 vaccinated mice. Graphs are presented as mean $\pm$ SEM (n.s. non-significant, * $p < 0.05$, ** $p < 0.001$, unpaired two-tailed Student's t -test).

3.4. Microglia at the Plaque Are Changed Following ACI-24 Vaccination

To analyse if ACI-24 vaccination affected microglial phenotypes, we investigated microglial recruitment to A β plaques (Figure 3A,B). We observed a trend towards an increased number of microglia at the plaques (Figure 3A and Supplementary Figure S4) and a trend towards increased CD68 coverage (Figure 3B and Supplementary Figure S4) following ACI-24 vaccination (transgenic mother offspring). Notably, there was a significant increase in the proportion of NLRP3 positive microglia at the plaque in the ACI-24 vaccinated mice (transgenic mother offspring) (Figure 3C,D), suggesting a local activation of plaque-associated microglia that may contribute to A β plaque reduction. However, bulk proteomic analysis of acutely isolated microglia from both transgenic mother and father offspring revealed no major changes of microglial phenotypes following ACI-24 vaccination (Supplementary Figure S5). Local changes may have not been captured by the bulk proteomic analysis, or may be less pronounced as both transgenic father and mother animals were included into the proteomic analysis. Overall, this suggests that the vaccine-mediated reduction in A β deposition may be a valid therapeutic intervention, as there are no excessive changes in microglial phenotypes. This observation is of particular relevance as excessive overactivation of microglia often leads to unwanted side effects that may compromise the therapeutic benefits.




Figure 3. Increased microglial activation at A β plaques can be observed in the offspring generated by the transgenic mother following ACI-24 vaccination. Statistical analysis of the average number of microglia recruited at the A β plaques (plaque-associated microglia) of 5 control and 6 ACI-24 vaccinated mice (transgenic mother offspring) (A). The number of Iba1+ plaque associated microglia was normalised to the A β area (as stained with 3552 antibody). Average CD68 signal was measured and normalised to the microglia number, revealing a trend towards increased CD68

coverage at the A β plaques (B). Double staining of Iba1 and NLRP3 reveals an increase in the proportion of NLRP3+ microglia at the A β plaque (as stained with Methoxy-X04) following ACI-24 vaccination (C,D). Scale bar: 20 μ m. Graphs are presented as mean $\pm$ SEM (n.s. non-significant, * $p < 0.05$, unpaired two-tailed Student's t -test).

3.5. Global Beneficial Microglial Effect of the ACI-24 Vaccination

In addition to bulk proteomic analysis of microglia, we also performed a bulk transcriptomic analysis of cerebrum (transgenic mother offspring) to exclude possible gene expression changes in other brain cells following ACI-24 vaccination. To this end, we analysed the expression of genes with the nCounter Glial Profiling Panel (Figure 4A and Supplementary Table S1) and the Neuropathology Panel (Figure 4B and Supplementary Table S2) (NanoString Technologies, Seattle, WA, USA) in the cerebrum of the vaccinated mice. The Glial Profiling Panel addresses the crosstalk between glial cells, peripheral immune cells and neurons by assessing cell stress and damage responses, inflammation, peripheral immune invasion, neurotransmission, glial cell homeostasis and activation. The Neuropathology Panel covers the main aspects of neurodegeneration. Expression levels of 757 (Glial Profiling Panel) or 760 (Neuropathology Panel) genes were normalised against the geometric mean of 12 (Glial Profiling Panel) or 9 (Neuropathology Panel) housekeeping genes. Using this comprehensive analysis, we detect only minor changes in bulk gene expression profiles, supporting the notion that ACI-24 vaccination does not trigger overt changes in gene expression profiles of brain cells (Figure 4A,B, Supplementary Tables S1 and S2). Among the few genes that were differentially expressed following ACI-24 vaccination, we detected a trend towards downregulation of the DAM genes *Trem2* (21%), *Cd68* (17%), *Cd163* (24%) and *Cst7* (55%) (Figure 4A and Supplementary Table S1), that is well in line with the beneficial effect of reduced A β deposition.




Figure 4. Bulk transcriptomic analysis from cerebrum of 6 ACI-24 vaccinated and 5 control mice (transgenic mother offspring). Volcano plots depict differentially expressed genes with the nCounter Glial Profiling Panel (A) and Neuropathology Panel (B). The negative log10 transformed p -value is plotted against the mean log2 transformed ratio between ACI-24 vaccinated and control animals. Horizontal dotted line depicts the p -value of 0.05, while the vertical lines represent changes in the expression of 15% as annotated. Genes with the p -value less than 0.05 are marked in red, while in grey

are those with a p -value larger than 0.05. Differentially expressed genes that are significant according to the p value of 0.05 (non FDR-corrected) and changed more than 15% are marked with their names.

To further support the hypothesis that microglia are globally less activated following ACI-24 vaccination, we analysed the morphology of microglia (transgenic mother offspring) that are not directly in contact with A β plaques (plaque-distant microglia) (Figure 5A). Sholl analysis of plaque-distant microglia revealed a trend to the increase in the ramification index in the ACI-24 vaccinated compared to control mice (Figure 5B). Accordingly, the circularity of Iba1+ cells, as well as the area of the cell, was significantly reduced (Figure 5C,D), revealing a more ramified microglial morphology in the ACI-24 vaccinated animals. In line with this, the cell perimeter was significantly increased in the ACI-24 vaccinated mice (Figure 5E).




Figure 5. Plaque-distant microglia show increased ramification following ACI-24 vaccination. Representative images and the respective Sholl analysis of the plaque-distant microglia (8–14 microglia per brain) in 5 control (in total 48 microglia) and 6 ACI-24 (in total 63 microglia) treated mice (transgenic mother offspring) (A). Microglia are depicted with Iba1, A β is visualised using 3552 antibody and nuclei using Hoechst. Scale bar: 50 μ m. Statistical analysis representing graphs for the ramification index (B), circularity (C), area (D) and perimeter (E) of Iba1+ cells. Graphs are presented as mean $\pm$ SEM (n.s. non-significant, ** $p < 0.001$). Kolmogorov–Smirnov test was performed to check if samples are following normal distribution, and then an unpaired two-tailed Student’s t -test or a Mann–Whitney test were carried out accordingly.

Together, these data suggest that ACI-24 vaccinated mice have less amoeboid and more ramified morphology of plaque-distant microglia compared to non-vaccinated controls. This morphological analysis is in line with the detected trend in transcriptional reduction of several DAM genes in association with the pronounced reduction of A β pathology following ACI-24 vaccination.

3.6. ACI-24 Reduces ApoE Protein Levels and Neuronal Injury

To further investigate the effect of vaccination with ACI-24, we assessed plaque related abnormalities such as the levels of ApoE (Figure 6A), the major constituent of A β plaques that promotes A β aggregation and deposition [56–58]. Furthermore, we evaluated BACE1 (Figure 6B), that was previously shown to accumulate in the dystrophic neurites that

surround A β plaques in APP transgenic mice [59]. The total ApoE coverage (transgenic mother offspring) was significantly reduced following ACI-24 vaccination (Figure 6C and Supplementary Figure S6A). The immunohistochemical analysis of BACE1 revealed reduced BACE1 staining in the ACI-24 vaccinated mice compared to controls (transgenic mother offspring), indicating significant reduction in plaque-associated neuritic dystrophies (Figure 6D and Supplementary Figure S6B). These observations correlate well with the reduction of A β plaque load post vaccination.




Figure 6. ACI-24 reduces ApoE protein levels and neuronal injury in the offspring generated by the transgenic mother. Representative images of control and ACI-24 vaccinated mice stained for nuclei (Hoechst), fibrillar A β (ThR), A β plaques (3552 antibody) and ApoE (A); and nuclei (Hoechst), fibrillar A β (ThR), A β plaques (NAB228 antibody) and BACE1 (dystrophic neurites) (B). Scale bar: 200 μ m. Statistical analysis of 5 control and 6 ACI-24 vaccinated mice (transgenic mother offspring) showing significant downregulation of both total ApoE (C) and BACE1 (D) coverage. Graphs are presented as mean $\pm$ SEM (* $p < 0.05$, ** $p < 0.001$, unpaired two-tailed Student's t -test).

In summary, these experiments demonstrated that vaccination with ACI-24 elicits a beneficial polyclonal antibody response that acts to diminish A β plaques and associ-

ated pathologies, including a reduction of ApoE and dystrophic neurites. Furthermore, the mechanism involves the normalisation of microglial morphological and molecular phenotypes, suggesting amelioration of neuroinflammation.

4. Discussion

This study assessed the efficacy of targeting A β with an active immunotherapy approach, using the ACI-24 vaccine for reducing the A β pathology in a progressive amyloidosis mouse model, APPPS1 [47]. ACI-24 immunisation resulted in substantial and sustained anti-A β 42 antibody titres that were robustly detected in all vaccinated animals. Despite the high intra-group variability (transgenic mother and father offspring), a consistent and significant reduction was observed for the A β coverage and A β plaque size in the ACI-24 vaccinated versus the control mice. Vaccination efficacy was associated with severity of the A β plaque pathology, suggesting that vaccination at earlier disease stages may provide a more favourable therapeutic outcome. Along these lines, the vaccination-mediated effects on the A β reduction were more prominently observed in the animals generated by the transgenic mother, which had lower A β burden compared to animals generated by the transgenic father.

To exclude the possibility that this unexpected difference in A β burden between transgenic mother and father APPPS1 offspring did not happen by chance, this effect should be further validated in a larger animal cohort as our findings may suggest a mechanism of maternal protection. Although the underlying mechanistic insight remains unknown, this protective effect may be mediated by estrogenic action, mitochondrial maternal contribution [60] or the transfer of anti-A β antibodies from the mother to the offspring [61]. Indeed, auto anti-A β antibodies have been already reported in humans and this was integral for the discovery of therapeutically relevant antibody aducanumab [19]. Moreover, maternal protection and transfer of anti-A β antibodies from the mother to the pups was recently described in the 5xFAD model following A β vaccination [61].

The robust reduction of the A β plaque load triggered by ACI-24 vaccine further translated into the beneficial reduction of dystrophic neurites, i.e., swellings in neurons that reflect abnormal axonal trafficking and accompany A β deposition [62,63]. Moreover, there was a reduction in the ApoE levels, a protein known to promote A β aggregation and deposition in the plaques [56–58].

The reduction of the A β plaque load following ACI-24 vaccination was in accordance with globally reduced microglial activation. mRNA analysis revealed a trend towards reduced DAM signatures such as *Trem2*, *Cd68*, *Cd163* and *Cst7* [10,16,18,64]. Accordingly, plaque-distant microglia showed more ramified morphology and reduced circularity following ACI-24 vaccination, suggesting reduced neuroinflammation. A similar effect of ramified microglial morphology following reduction of plaque load was recently observed with targeted deletion of BACE1 in 5xFAD microglia [65]. The beneficial resolution of inflammation may be helpful to reduce side effects such as ARIA that were observed in the clinical trials with anti-A β targeting mAbs [66] or A β targeting vaccines [36–40]. In contrast to globally reduced microglial activation following ACI-24 vaccination, local microglial activation, assessed by the increase in the proportion of NLRP3-positive plaque-associated microglia, may contribute to reduced A β plaque burden [9,67,68]. This is in line with the increased recruitment of microglia to A β plaques observed following aducanumab treatment and the proposed mechanism of Fc γ R-mediated phagocytosis of pathological A β [19,69]. Taken together, this regulation of microglial inflammatory phenotypes speaks positively for a safe and successful therapeutic intervention where beneficial microglial responses are feasible without detrimental and uncontrolled microglial overstimulation.

In summary, the key findings of our study are that vaccination with ACI-24 elicits a robust and sustained antibody response that translates into a beneficial effect on plaque load, reducing A β plaque-associated ApoE, dystrophic neurites and microglial pathology. Furthermore, these data—albeit generated by using a transgenic animal model—suggest that the efficacy of the vaccination with ACI-24 could be linked to the severity of A β

deposition, highlighting early and even preventive therapeutic use to modify A β plaque deposition.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/cells12010079/s1>, Figure S1: Higher A β plaque load in transgenic father compared to transgenic mother offspring; Figure S2: ACI-24 has no major impact on A β plaque pathology in the offspring generated by the transgenic father; Figure S3: ACI-24 reduces plaque pathology in the transgenic mother offspring; Figure S4: ACI-24 shows a trend towards increased microglial activation at the A β plaque in the transgenic mother offspring; Figure S5: No major changes in microglial proteome following ACI-24 vaccination; Figure S6: ACI-24 reduces ApoE protein levels and neuronal injury in the transgenic mother offspring; Table S1: Table of differentially expressed genes using Glial Profiling Panel; Table S2: Table of differentially expressed genes using Neuropathology Panel.

Author Contributions: Conceptualisation, J.R.N., A.P., M.K.-V. and S.T.; software, J.R.N. and C.B. (Chiara Bordier); formal analysis, J.R.N., S.A.M., C.B. (Chiara Bordier), S.K., A.H., S.F.L. and P.M.; investigation J.R.N., L.D., S.A.M., A.B., C.B. (Chiara Bordier), S.K., K.B., A.C., C.G., M.W. and R.F.; resources: M.V., E.F., C.G., M.W., R.F., C.B. (Chiara Babolin), P.M., A.P. and M.K.-V.; writing—original draft preparation, J.R.N. and S.T.; writing—review and editing J.R.N., M.V., E.F., L.D., S.A.M., A.B., C.B. (Chiara Bordier), S.K., A.H., K.B., A.C., C.G., M.W., R.F., S.F.L., C.B. (Chiara Babolin), P.M., A.P., M.K.-V. and S.T.; visualisation, J.R.N., S.A.M. and S.K.; supervision, A.H., S.F.L. and S.T.; project administration, J.R.N. and S.T.; funding acquisition, S.T. and A.P. All authors have read and agreed to the published version of the manuscript.

Funding: S.T. is supported by the Alzheimer Forschung Initiative e.v. (grant number 18014). This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy-ID 390857198) and by the Federal Ministry of Education and Research through grant JPND PMD-AD. S.T. was supported by AC Immune SA.

Institutional Review Board Statement: All animal experiments were carried out in accordance with the German animal welfare law and approval for this work has been issued to DZNE (ROB-55.2-2532.Vet_02-17-153) and Helmholtz Zentrum München (ROB-55.2-2532.Vet_03-17-68) by the government of Upper Bavaria.

Informed Consent Statement: Not applicable.

Data Availability Statement: The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD038665. Source data are provided with this manuscript.

Acknowledgments: The authors thank Michael Heide and Oliver Weigert from the “Digital Single Molecule Quantification” Core Facility of the German Cancer Consortium (DKTK, Munich Site) for the help with the NanoString measurements. We are thankful to Steffanie Heindl and Arthur Liesz for the assistance with the microglia morphology analysis. We thank Mathias Jucker (Hertie-Institute for Clinical Brain Research, University of Tübingen, Germany) for providing the APPPS1 mice. We thank Matthias Prestel for critically reading the manuscript.

Conflicts of Interest: M.V., E.F., C.B. (Chiara Babolin), P.M., A.P. and M.K.-V. are employees of the AC Immune SA. All other authors declare that they have no conflict of interest.

References

1. Hardy, J.A.; Higgins, G.A. Alzheimer's Disease: The amyloid cascade hypothesis. *Science* **1992**, *256*, 184–185. [[CrossRef](#)] [[PubMed](#)]
2. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's Disease: Progress and problems on the road to therapeutics. *Science* **2002**, *297*, 353–356. [[CrossRef](#)] [[PubMed](#)]
3. Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol. Med.* **2016**, *8*, 595–608. [[CrossRef](#)] [[PubMed](#)]
4. Rogers, J.; Strohmeier, R.; Kovelowski, C.J.; Li, R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. *GLIA* **2002**, *40*, 260–269. [[CrossRef](#)]
5. Lee, C.Y.; Landreth, G.E. The role of microglia in amyloid clearance from the AD brain. *J. Neural Transm.* **2010**, *117*, 949–960. [[CrossRef](#)]

6. Liu, Z.; Condello, C.; Schain, A.; Harb, R.; Grutzendler, J. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid- β phagocytosis. *J. Neurosci.* **2010**, *30*, 17091–17101. [[CrossRef](#)]
7. Njie, E.G.; Boelen, E.; Stassen, F.R.; Steinbusch, H.W.; Borchelt, D.R.; Streit, W.J. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. *Neurobiol. Aging* **2012**, *33*, 195.e1–195.e12. [[CrossRef](#)]
8. Krabbe, G.; Halle, A.; Matyash, V.; Rinnenthal, J.L.; Eom, G.D.; Bernhardt, U.; Miller, K.R.; Prokop, S.; Kettenmann, H.; Heppner, F.L. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. *PLoS ONE* **2013**, *8*, e60921. [[CrossRef](#)]
9. Daria, A.; Colombo, A.; Llovera, G.; Hampel, H.; Willem, M.; Liesz, A.; Haass, C.; Tahirovic, S. Young microglia restore amyloid plaque clearance of aged microglia. *EMBO J.* **2017**, *36*, 583–603.
10. Sebastian Monasor, L.; Müller, S.A.; Colombo, A.V.; Tanriover, G.; König, J.; Roth, S.; Liesz, A.; Berghofer, A.; Piechotta, A.; Prestel, M.; et al. Fibrillar A β triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. *Elife* **2020**, *9*, 1–33. [[CrossRef](#)]
11. Efthymiou, A.G.; Goate, A.M. Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. *Mol. Neurodegener.* **2017**, *12*, 43. [[CrossRef](#)] [[PubMed](#)]
12. Podleśny-Drabiniok, A.; Marcora, E.; Goate, A.M. Microglial phagocytosis: A disease-associated process emerging from Alzheimer's disease genetics. *Trends Neurosci.* **2020**, *43*, 965–979. [[CrossRef](#)] [[PubMed](#)]
13. Hickman, S.E.; Allison, E.K.; El Khoury, J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *J. Neurosci.* **2008**, *28*, 8354–8360. [[CrossRef](#)] [[PubMed](#)]
14. Butovsky, O.; Jedrychowski, M.P.; Cialic, R.; Krasemann, S.; Murugaiyan, G.; Fanek, Z.; Greco, D.J.; Wu, P.M.; Doykan, C.E.; Kiner, O.; et al. Targeting miR-155 restores abnormal microglia and attenuates disease in SOD1 mice. *Ann. Neurol.* **2015**, *77*, 75–99. [[CrossRef](#)] [[PubMed](#)]
15. Holtman, I.R.; Raj, D.D.; Miller, J.A.; Schaafsma, W.; Yin, Z.; Brouwer, N.; Wes, P.D.; Möller, T.; Orre, M.; Kamphuis, W.; et al. Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis. *Acta Neuropathol. Commun.* **2015**, *3*, 31. [[CrossRef](#)]
16. Keren-Shaul, H.; Spinrad, A.; Weiner, A.; Matcovitch-Natan, O.; Dvir-Szternfeld, R.; Ulland, T.K.; David, E.; Baruch, K.; Lara-Astaiso, D.; Toth, B.; et al. A unique microglia type associated with restricting development of Alzheimer's Disease. *Cell* **2017**, *169*, 1276–1290.e1217. [[CrossRef](#)]
17. Yin, Z.; Raj, D.; Saiepour, N.; Van Dam, D.; Brouwer, N.; Holtman, I.R.; Eggen, B.J.L.; Möller, T.; Tamm, J.A.; Abdourahman, A.; et al. Immune hyperreactivity of A β plaque-associated microglia in Alzheimer's disease. *Neurobiol. Aging* **2017**, *55*, 115–122. [[CrossRef](#)]
18. Krasemann, S.; Madore, C.; Cialic, R.; Baufeld, C.; Calcagno, N.; El Fatimy, R.; Beckers, L.; O'Loughlin, E.; Xu, Y.; Fanek, Z.; et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. *Immunity* **2017**, *47*, 566–581.e569. [[CrossRef](#)]
19. Sevigny, J.; Chiao, P.; Bussiere, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. *Nature* **2016**, *537*, 50–56. [[CrossRef](#)]
20. Song, C.; Shi, J.; Zhang, P.; Zhang, Y.; Xu, J.; Zhao, L.; Zhang, R.; Wang, H.; Chen, H. Immunotherapy for Alzheimer's disease: Targeting β -amyloid and beyond. *Transl. Neurodegener.* **2022**, *11*, 18. [[CrossRef](#)]
21. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* **1999**, *400*, 173–177. [[CrossRef](#)] [[PubMed](#)]
22. Gilman, S.; Koller, M.; Black, R.S.; Jenkins, L.; Griffith, S.G.; Fox, N.C.; Eisner, L.; Kirby, L.; Rovira, M.B.; Forette, F.; et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. *Neurology* **2005**, *64*, 1553–1562. [[CrossRef](#)] [[PubMed](#)]
23. Hock, C.; Nitsch, R.M. Clinical observations with AN-1792 using TAPIR analyses. *Neuro-Degener. Dis.* **2005**, *2*, 273–276. [[CrossRef](#)] [[PubMed](#)]
24. Orgogozo, J.M.; Gilman, S.; Dartigues, J.F.; Laurent, B.; Puel, M.; Kirby, L.C.; Jouanny, P.; Dubois, B.; Eisner, L.; Flitman, S.; et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. *Neurology* **2003**, *61*, 46–54. [[CrossRef](#)] [[PubMed](#)]
25. Monsonogo, A.; Imitola, J.; Petrovic, S.; Zota, V.; Nemirovsky, A.; Baron, R.; Fisher, Y.; Owens, T.; Weiner, H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 5048–5053. [[CrossRef](#)] [[PubMed](#)]
26. Tabira, T. Immunization therapy for Alzheimer disease: A comprehensive review of active immunization strategies. *Tohoku J. Exp. Med.* **2010**, *220*, 95–106. [[CrossRef](#)]
27. Delrieu, J.; Ousset, P.J.; Caillaud, C.; Vellas, B. "Clinical trials in Alzheimer's disease": Immunotherapy approaches. *J. Neurochem.* **2012**, *120* (Suppl. 1), 186–193. [[CrossRef](#)]
28. Lowe, S.L.; Willis, B.A.; Hawdon, A.; Natanegara, F.; Chua, L.; Foster, J.; Shcherbinin, S.; Ardayfio, P.; Sims, J.R. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. *Alzheimers Dement.* **2021**, *7*, e12112. [[CrossRef](#)]
29. Fillit, H.; Green, A. Aducanumab and the FDA—Where are we now? *Nat. Rev. Neurol.* **2021**, *17*, 129–130. [[CrossRef](#)]

30. Swanson, C.J.; Zhang, Y.; Dhadda, S.; Wang, J.; Kaplow, J.; Lai, R.Y.K.; Lannfelt, L.; Bradley, H.; Rabe, M.; Koyama, A.; et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A β protofibril antibody. *Alzheimers Res. Ther.* **2021**, *13*, 80. [[CrossRef](#)]
31. Mintun, M.A.; Lo, A.C.; Duggan Evans, C.; Wessels, A.M.; Ardayfio, P.A.; Andersen, S.W.; Shcherbinin, S.; Sparks, J.; Sims, J.R.; Brys, M.; et al. Donanemab in early Alzheimer's disease. *N. Engl. J. Med.* **2021**, *384*, 1691–1704. [[CrossRef](#)] [[PubMed](#)]
32. Salloway, S.; Farlow, M.; McDade, E.; Clifford, D.B.; Wang, G.; Llibre-Guerra, J.J.; Hitchcock, J.M.; Mills, S.L.; Santacruz, A.M.; Aschenbrenner, A.J.; et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. *Nat. Med.* **2021**, *27*, 1187–1196. [[CrossRef](#)] [[PubMed](#)]
33. Uhlmann, R.E.; Rother, C.; Rasmussen, J.; Schelle, J.; Bergmann, C.; Ullrich Gavilanes, E.M.; Fritsch, S.K.; Buehler, A.; Baumann, F.; Skodras, A.; et al. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. *Nat. Neurosci.* **2020**, *23*, 1580–1588. [[CrossRef](#)]
34. Kwan, P.; Konno, H.; Chan, K.Y.; Baum, L. Rationale for the development of an Alzheimer's disease vaccine. *Hum. Vaccines Immunother.* **2020**, *16*, 645–653. [[CrossRef](#)] [[PubMed](#)]
35. Salloway, S.; Sperling, R.; Brashear, H.R. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. *N. Engl. J. Med.* **2014**, *370*, 1460. [[CrossRef](#)] [[PubMed](#)]
36. Farlow, M.R.; Andreasen, N.; Riviere, M.E.; Vostiar, I.; Vitaliti, A.; Sovago, J.; Caputo, A.; Winblad, B.; Graf, A. Long-term treatment with active A β immunotherapy with CAD106 in mild Alzheimer's disease. *Alzheimers Res. Ther.* **2015**, *7*, 23. [[CrossRef](#)]
37. Pasquier, F.; Sadowsky, C.; Holstein, A.; Leterme, G.; Peng, Y.; Jackson, N.; Fox, N.C.; Ketter, N.; Liu, E.; Ryan, J.M. Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridifcar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. *J. Alzheimers Dis.* **2016**, *51*, 1131–1143. [[CrossRef](#)]
38. Hull, M.; Sadowsky, C.; Arai, H.; Le Prince Leterme, G.; Holstein, A.; Booth, K.; Peng, Y.; Yoshiyama, T.; Suzuki, H.; Ketter, N.; et al. Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease. *Curr. Alzheimer Res.* **2017**, *14*, 696–708. [[CrossRef](#)]
39. Vandenberghe, R.; Riviere, M.E.; Caputo, A.; Sovago, J.; Maguire, R.P.; Farlow, M.; Marotta, G.; Sanchez-Valle, R.; Scheltens, P.; Ryan, J.M.; et al. Active A β immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. *Alzheimers Dement.* **2017**, *3*, 10–22. [[CrossRef](#)]
40. Lacosta, A.M.; Pascual-Lucas, M.; Pesini, P.; Casabona, D.; Pérez-Grijalba, V.; Marcos-Campos, I.; Sarasa, L.; Canudas, J.; Badi, H.; Monleón, I.; et al. Safety, tolerability and immunogenicity of an active anti-A β (40) vaccine (ABvac40) in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, phase I trial. *Alzheimers Res. Ther.* **2018**, *10*, 12. [[CrossRef](#)]
41. Muhs, A.; Hickman, D.T.; Pihlgren, M.; Chuard, N.; Giriens, V.; Meerschman, C.; van der Auwera, I.; van Leuven, F.; Sugawara, M.; Weingertner, M.C.; et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 9810–9815. [[CrossRef](#)] [[PubMed](#)]
42. Belichenko, P.V.; Madani, R.; Rey-Bellet, L.; Pihlgren, M.; Becker, A.; Plassard, A.; Vuillermot, S.; Giriens, V.; Nosheny, R.L.; Kleschevnikov, A.M.; et al. An anti-beta-amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome. *PLoS ONE* **2016**, *11*, e0152471. [[CrossRef](#)] [[PubMed](#)]
43. Hickman, D.T.; Lopez-Deber, M.P.; Ndao, D.M.; Silva, A.B.; Nand, D.; Pihlgren, M.; Giriens, V.; Madani, R.; St-Pierre, A.; Karastaneva, H.; et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. *J. Biol. Chem.* **2011**, *286*, 13966–13976. [[CrossRef](#)]
44. Saido, T.C.; Iwatsubo, T.; Mann, D.M.; Shimada, H.; Ihara, Y.; Kawashima, S. Dominant and differential deposition of distinct beta-amyloid peptide species, A β 42 and A β 40, in senile plaques. *Neuron* **1995**, *14*, 457–466. [[CrossRef](#)]
45. Pike, C.J.; Overman, M.J.; Cotman, C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. *J. Biol. Chem.* **1995**, *270*, 23895–23898. [[CrossRef](#)]
46. Vukicevic, M.; Fiorini, E.; Siegert, S.; Carpintero, R.; Rincon-Restrepo, M.; Lopez-Deber, P.; Piot, N.; Ayer, M.; Rentero, I.; Babolin, C.; et al. An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer's disease: Pyroglutamate amyloid beta. *Brain Commun.* **2022**, *4*, fcac022. [[CrossRef](#)] [[PubMed](#)]
47. Radde, R.; Bolmont, T.; Kaeser, S.A.; Coomaraswamy, J.; Lindau, D.; Stoltze, L.; Calhoun, M.E.; Jaggi, F.; Wolburg, H.; Gengler, S.; et al. A β 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. *EMBO Rep.* **2006**, *7*, 940–946. [[CrossRef](#)] [[PubMed](#)]
48. Piedrahita, J.A.; Zhang, S.H.; Hagaman, J.R.; Oliver, P.M.; Maeda, N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 4471–4475. [[CrossRef](#)]
49. Yamasaki, A.; Eimer, S.; Okochi, M.; Smialowska, A.; Kaether, C.; Baumeister, R.; Haass, C.; Steiner, H. The GxGD motif of presenilin contributes to catalytic function and substrate identification of gamma-secretase. *J. Neurosci.* **2006**, *26*, 3821–3828. [[CrossRef](#)]
50. Heindl, S.; Gesierich, B.; Benakis, C.; Llovera, G.; Duering, M.; Liesz, A. Automated morphological analysis of microglia after stroke. *Front. Cell Neurosci.* **2018**, *12*, 106. [[CrossRef](#)]
51. Colombo, A.; Dinkel, L.; Müller, S.A.; Sebastian Monasor, L.; Schifferer, M.; Cantuti-Castelvetri, L.; König, J.; Vidatic, L.; Bremova-Ertl, T.; Lieberman, A.P.; et al. Loss of NPC1 enhances phagocytic uptake and impairs lipid trafficking in microglia. *Nat. Commun.* **2021**, *12*, 1158. [[CrossRef](#)] [[PubMed](#)]

52. Hughes, C.S.; Moggridge, S.; Müller, T.; Sorensen, P.H.; Morin, G.B.; Krijgsveld, J. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. *Nat. Protoc.* **2019**, *14*, 68–85. [\[CrossRef\]](#)
53. Demichev, V.; Messner, C.B.; Vernardis, S.I.; Lilley, K.S.; Ralser, M. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput. *Nat. Methods* **2020**, *17*, 41–44. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Tusher, V.G.; Tibshirani, R.; Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 5116–5121. [\[CrossRef\]](#) [\[PubMed\]](#)
55. Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M.Y.; Geiger, T.; Mann, M.; Cox, J. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **2016**, *13*, 731–740. [\[CrossRef\]](#)
56. Ma, J.; Yee, A.; Brewer, H.B.; Jr Das, S.; Potter, H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. *Nature* **1994**, *372*, 92–94. [\[CrossRef\]](#)
57. Huynh, T.V.; Liao, F.; Francis, C.M.; Robinson, G.O.; Serrano, J.R.; Jiang, H.; Roh, J.; Finn, M.B.; Sullivan, P.M.; Esparza, T.J.; et al. Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β -amyloidosis. *Neuron* **2017**, *96*, 1013–1023.e1014. [\[CrossRef\]](#)
58. Liu, C.C.; Zhao, N.; Fu, Y.; Wang, N.; Linares, C.; Tsai, C.W.; Bu, G. ApoE4 accelerates early seeding of amyloid pathology. *Neuron* **2017**, *96*, 1024–1032.e1023. [\[CrossRef\]](#)
59. Kandalepas, P.C.; Sadleir, K.R.; Eimer, W.A.; Zhao, J.; Nicholson, D.A.; Vassar, R. The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques. *Acta Neuropathol.* **2013**, *126*, 329–352. [\[CrossRef\]](#)
60. Viña, J.; Lloret, A. Why women have more Alzheimer's disease than men: Gender and mitochondrial toxicity of amyloid-beta peptide. *J. Alzheimers Dis.* **2010**, *20* (Suppl. S2), S527–S533. [\[CrossRef\]](#)
61. Illouz, T.; Nicola, R.; Ben-Shushan, L.; Madar, R.; Biragyn, A.; Okun, E. Maternal antibodies facilitate Amyloid- β clearance by activating Fc-receptor-Syk-mediated phagocytosis. *Commun. Biol.* **2021**, *4*, 329. [\[CrossRef\]](#)
62. Stokin, G.B.; Lillo, C.; Falzone, T.L.; Brusch, R.G.; Rockenstein, E.; Mount, S.L.; Raman, R.; Davies, P.; Masliah, E.; Williams, D.S.; et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. *Science* **2005**, *307*, 1282–1288. [\[CrossRef\]](#) [\[PubMed\]](#)
63. Meyer-Luehmann, M.; Spire-Jones, T.L.; Prada, C.; Garcia-Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D.M.; Bacskai, B.J.; Hyman, B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. *Nature* **2008**, *451*, 720–724. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Nguyen, A.T.; Wang, K.; Hu, G.; Wang, X.; Miao, Z.; Azevedo, J.A.; Suh, E.; Van Deerlin, V.M.; Choi, D.; Roeder, K.; et al. APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease. *Acta Neuropathol.* **2020**, *140*, 477–493. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Singh, N.; Das, B.; Zhou, J.; Hu, X.; Yan, R. Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. *Sci. Adv.* **2022**, *8*, eabo3610. [\[CrossRef\]](#)
66. Avgerinos, K.I.; Ferrucci, L.; Kapogiannis, D. Effects of monoclonal antibodies against amyloid- β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. *Ageing Res. Rev.* **2021**, *68*, 101339. [\[CrossRef\]](#)
67. Chakrabarty, P.; Li, A.; Ceballos-Diaz, C.; Eddy, J.A.; Funk, C.C.; Moore, B.; DiNunno, N.; Rosario, A.M.; Cruz, P.E.; Verbeeck, C.; et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. *Neuron* **2015**, *85*, 519–533. [\[CrossRef\]](#)
68. Lewcock, J.W.; Schlepckow, K.; Di Paolo, G.; Tahirovic, S.; Monroe, K.M.; Haass, C. Emerging microglia biology defines novel therapeutic approaches for Alzheimer's Disease. *Neuron* **2020**, *108*, 801–821. [\[CrossRef\]](#)
69. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nat. Med.* **2000**, *6*, 916–919. [\[CrossRef\]](#)

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.